Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment

Abstract

This article synthesizes the evidence on the cost-effectiveness of renal replacement therapy and discusses the findings in light of the frequent practice of using the cost-effectiveness of hemodialysis as a benchmark of societal willingness to pay. The authors conducted a meta-analytic review of the medical and economic literature for economic evaluations of hemodialysis, peritoneal dialysis, and kidney transplantation. Cost-effectiveness ratios were translated into 2000 U.S. dollars per life-year (LY) saved. Thirteen studies published between 1968 and 1998 provided such information. The cost-effectiveness of center hemodialysis remained within a narrow range of $55,000 to $80,000/LY in most studies despite considerable variation in methodology and imputed costs. The cost-effectiveness of home hemodialysis was found to be between $33,000 and $50,000/LY. Kidney transplantation, however, has become more cost-effective over time, approaching $10,000/LY. Estimates of the cost per life-year gained from hemodialysis have been remarkably stable over the past 3 decades, after adjusting for price levels. Uses of the cost-effectiveness ratio of $55,000/LY for center hemodialysis as a lower boundary of society’s willingness to pay for an additional life-year can be supported under certain assumptions.

Keywords

cost-effectiveness analysis dialysis kidney transplantation meta-analysis

Get full access to this article

View all access options for this article.

References

Drummond MF , Stoddart GL , Torrance GW . Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford, UK: Oxford University Press; 1997.

Gold MR , Siegel JE , Russell LB , Weinstein MC . Cost-effectiveness in Health and Medicine. Oxford, UK: Oxford University Press; 1996.

Quinton W , Dillard D , Scribner B. Cannulation of blood vessels for prolonged hemodialysis. Trans Asian Soc Artif Intern Organs. 1960;6:104.

Popovich RP , Moncrief JW , Nolph KD , Ghods AJ , Twardowski Z , Pyle WK . Continuous ambulatory peritoneal dialysis. Ann Int Med. 1978;88:449-456.

Merrill JP , Murray JE , Harrison JH , et al. Successful homo-transplantation of the human kidney between identical twins. JAMA. 1956;160:277-282.

Murray J , Merill J , Harrison J , Wilson K , Damin G. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med. 1963;269:1315-1323.

Nissenson AR , Prichard SS , Cheng IK , et al. ESRD modality selection into the 21st century: the importance of non-medical factors. ASAIO J. 1997;43:143-150.

Ayanian JZ , Cleary PD , Weissman JS , Epstein AM . The effect of patients’ preferences on racial differences in access to renal transplantation. N Engl J Med. 1999;341:1661-1669.

Winkelmayer WC , Glynn RJ , Levin R , Owen W , Avorn J. Late referral and modality choice in end-stage renal disease. Kidney Int. 2001;60:1547-1554.

10.

Nixon J , Khan KS , Kleijnen J. Summarizing economic evaluations in systematic reviews: a new approach. Br Med J. 2001;322: 1596-1598.

11.

Available from http://www.oecd.org/std/nadata.htm.

12.

Available from ftp://ftp.bls.gov/pub/special.requests/cpi/cpiai.txt.

13.

Klarman HE , Francis JO , Rosenthal GD . Cost effectiveness analysis applied to the treatment of chronic renal disease. Med Care. 1968;6:48-54.

14.

Buxton MJ , West RR . Cost-benefit analysis of long-term hemodialysis for chronic renal failure. Br Med J. 1975;2:376-379.

15.

Stange PV , Sumner AT . Predicting treatment costs and life-expectancy for end-stage renal disease. N Engl J Med. 1978;298:372-378.

16.

Roberts SD , Maxwell DR , Gross TL . Cost-effective care of end-stage renal disease: a billion dollar question. Ann Int Med. 1980;92(pt 1):243-248.

17.

Ludbrook A. A cost-effectiveness analysis of the treatment of chronic renal failure. Appl Econ. 1981;13:337-350.

18.

Churchill DN , Lemon BC , Torrance GW . A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis and hospital hemodialysis. Med Decis Making. 1984;4:489-500.

19.

Schersten T , Brynger H , Karlberg I , Jonsson E. Cost-effectiveness of organ transplantation. Int J Tech Assess Health Care. 1986;2:545-552.

20.

Garner TI , Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care. 1987;25:25-34.

21.

Sesso R , Eisenberg JM , Stabile C , Draibe S , Ajzen H , Ramos O. Cost-effectiveness analysis of the treatment of end-stage renal disease in Brazil. Int J Tech Assess Health Care. 1990;6:107-114.

22.

Croxson BE , Ashton T. A cost effectiveness analysis of the treatment of end stage renal failure. N Z Med J. 1990;103:171-174.

23.

Karlberg I , Nyberg G. Cost-effectiveness studies of renal transplantation. Int J Tech Assess Health Care. 1995;11:611-622.

24.

Laupacis A , Keown P , Pus N , Krueger H , Ferguson B , Wong C , Muirhead N. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50:235-242.

25.

De Vit GA , Ramsteijn PG , De Charro FT . Economic evaluation of end stage renal disease treatment. Health Policy. 1998;44:215-232.

26.

CANUSA Peritoneal Dialysis Study Group . Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol. 1996;7:198-207.

27.

Maiorca R , Brunori G , Zubani R , Cancarini GC , Manili L , Camerini C , Movilli E , Pola A , D’Avolio G , Gelatti U. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients: a longitudinal study. Nephrol Dial Transplant. 1995;10:2295-2305.

28.

Tengs TO , Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583-637.

29.

Sackett DL , Torrance GW . The utility of different health states as perceived by the general public. J Chronic Dis. 1978;31:697-704.

30.

US House of Representatives . A bill to amend Titles II and XVIII of the Social Security Act to make improvements in the End-Stage Renal Disease Program presently authorized under Section 226. HR 8423, 95th Cong, 1st sess, 1977.

31.

Constrained resources. In: Hunink MGM , Glasziou PP , Siegel JE , Weeks JC , Pliskin JS , Elstein AS , Weinstein MC , editors. Decision Analysis in Health and Medicine: Integrating Evidence and Values. Cambridge, UK: Cambridge University Press; 2001, p. 245-304.

32.

Huse DM , Russell MW , Miller JD , Kraemer DF , D’Agostino RB , Ellison RC , Hartz SC . Cost-effectiveness of statins. Am J Cardiol. 1998;82:1357-1363.

33.

NCQA’s health plan report card. Available at: http://hprc.ncqa.org/.

34.

Eddy DM . Screening for cervical cancer. Ann Int Med. 1990; 113:214-226.

35.

Drummond MF , Torrance GW , Mason J.

Cost-effectiveness league tables: more harm than good?

Soc Sci Med. 1993;37:33-40.